Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Oncolytic viruses aim to specifically kill tumor cells. A major challenge is the effective targeting of disseminated tumors in vivo. We retargeted herpes simplex virus (HSV) tropism to HER-2 oncoprotein p185, overexpressed in ovary and breast cancers. The HER-2-retargeted R-LM249 exclusively infects...

Full description

Saved in:
Bibliographic Details
Main Authors: Patrizia Nanni, Valentina Gatta, Laura Menotti, Carla De Giovanni, Marianna Ianzano, Arianna Palladini, Valentina Grosso, Massimiliano Dall'ora, Stefania Croci, Giordano Nicoletti, Lorena Landuzzi, Manuela Iezzi, Gabriella Campadelli-Fiume, Pier-Luigi Lollini
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2013
Subjects:
Immunologic diseases. Allergy
RC581-607
Biology (General)
QH301-705.5
Online Access:https://doaj.org/article/45fe9d4027634cfe86e1eaff9514f27a
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/45fe9d4027634cfe86e1eaff9514f27a

Similar Items